PURPOSE: To explore patient goals and quality of life (QOL) via a prospective registry and compare fertility preservation (FP) outcomes before, during, and after cancer therapy. METHODS: Of 35 patients entering the registry from 3/2008 to 3/2010, 29/35 completed the study survey and agreed to follow-up, and 31/35 completed treatment. Survey results and FP outcomes were analyzed. RESULTS: Most patients rated the impact of cancer treatment on fertility of highest importance at baseline and 1-year follow-up. QOL scores were overall positive at both intervals. Patients naïve to any cancer treatment (n = 12) had more gametes frozen than patients with prior cancer treatment (n = 19) with no difference in age or gonadotropin dosage. For patients awaiting cancer treatment, the median time from consultation to oocyte retrieval was 25 days. Cancer treatment sequalae posed challenges to optimal FP outcomes. CONCLUSIONS: Fertility preservation remains a significant issue for cancer patients. With early reproductive endocrinologist referral, cancer treatment delay is minimized and FP outcomes are optimized.
PURPOSE: To explore patient goals and quality of life (QOL) via a prospective registry and compare fertility preservation (FP) outcomes before, during, and after cancer therapy. METHODS: Of 35 patients entering the registry from 3/2008 to 3/2010, 29/35 completed the study survey and agreed to follow-up, and 31/35 completed treatment. Survey results and FP outcomes were analyzed. RESULTS: Most patients rated the impact of cancer treatment on fertility of highest importance at baseline and 1-year follow-up. QOL scores were overall positive at both intervals. Patients naïve to any cancer treatment (n = 12) had more gametes frozen than patients with prior cancer treatment (n = 19) with no difference in age or gonadotropin dosage. For patients awaiting cancer treatment, the median time from consultation to oocyte retrieval was 25 days. Cancer treatment sequalae posed challenges to optimal FP outcomes. CONCLUSIONS: Fertility preservation remains a significant issue for cancerpatients. With early reproductive endocrinologist referral, cancer treatment delay is minimized and FP outcomes are optimized.
Authors: Camille T C Hammond; Ellen B Beckjord; Neeraj K Arora; Keith M Bellizzi; Diana D Jeffery; Noreen M Aziz Journal: Fertil Steril Date: 2008-02-20 Impact factor: 7.329
Authors: Jaime M Knopman; Nicole Noyes; Sheeva Talebian; Lewis C Krey; James A Grifo; Frederick Licciardi Journal: Fertil Steril Date: 2008-09-18 Impact factor: 7.329
Authors: Zsolt P Nagy; Ching-Chien Chang; Daniel B Shapiro; Diana Patricia Bernal; Carlene W Elsner; Dorothy Mitchell-Leef; Andrew A Toledo; Hilton I Kort Journal: Fertil Steril Date: 2008-08-09 Impact factor: 7.329
Authors: Eden R Cardozo; Alexcis P Thomson; Anatte E Karmon; Kristy A Dickinson; Diane L Wright; Mary E Sabatini Journal: J Assist Reprod Genet Date: 2015-01-18 Impact factor: 3.412
Authors: Sharrόn L Manuel; Molly B Moravek; Rafael Confino; Kristin N Smith; Angela K Lawson; Susan C Klock; Mary Ellen Pavone Journal: J Assist Reprod Genet Date: 2019-12-11 Impact factor: 3.412
Authors: Charlotte Sonigo; Nelly Frydman; Anne Mayeur; Vincent Puy; Victoria Windal; Laetitia Hesters; Vanessa Gallot; Alexandra Benoit; Michael Grynberg Journal: J Assist Reprod Genet Date: 2021-04-01 Impact factor: 3.357